GE HealthCare Expands PET Imaging Capabilities with CE-Marked Cyclotron and Copper-64 Production
Event summary
- GE HealthCare's MINItrace Magni cyclotron received CE Mark approval on October 15, 2026.
- PETtrace Solid Target Platform now supports Copper-64 production, expanding beyond Gallium-68.
- MINItrace Magni features compact design, automation, and integration with TRACERcenter Solutions.
- Copper-64 production enables theranostics research for prostate cancer and HER2-positive breast cancer.
The big picture
GE HealthCare's advancements in PET imaging technology come as theranostics and molecular imaging demand grows across oncology, neurology, and cardiology. The company is positioning itself as a key player in enabling local production of critical radioisotopes, reducing reliance on external suppliers. With over 40 years of experience in cyclotron technology, GE HealthCare is expanding its platform to support emerging radiopharmaceutical research and clinical applications.
What we're watching
- Theranostics Growth
- How Copper-64's role in theranostics will impact GE HealthCare's position in oncology imaging.
- Local Production Trends
- The pace at which healthcare providers adopt local PET radioisotope production capabilities.
- Regulatory Expansion
- Whether GE HealthCare can secure additional regulatory approvals for MINItrace Magni in key markets.